King Wealth lifted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 53,043 shares of the company’s stock after acquiring an additional 848 shares during the quarter. Johnson & Johnson accounts for 1.8% of King Wealth’s investment portfolio, making the stock its 17th largest position. King Wealth’s holdings in Johnson & Johnson were worth $8,780,000 as of its most recent filing with the SEC.
Several other large investors have also recently made changes to their positions in the stock. Independent Advisor Alliance increased its stake in Johnson & Johnson by 0.9% during the 2nd quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock worth $25,380,000 after buying an additional 1,327 shares during the period. Peak Asset Management LLC increased its stake in Johnson & Johnson by 9.3% during the 1st quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after buying an additional 1,171 shares during the period. Nisa Investment Advisors LLC increased its stake in Johnson & Johnson by 0.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock worth $116,071,000 after buying an additional 6,836 shares during the period. Vaughan Nelson Investment Management L.P. increased its stake in Johnson & Johnson by 21.8% during the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock worth $140,050,000 after buying an additional 161,687 shares during the period. Finally, Tekla Capital Management LLC increased its stake in Johnson & Johnson by 12.8% during the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock worth $111,876,000 after buying an additional 82,100 shares during the period. 68.40% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on JNJ shares. Morgan Stanley cut their target price on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Friday. HSBC assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective on the stock. Barclays increased their price objective on shares of Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research report on Thursday, October 12th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 26th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $169.19.
Johnson & Johnson Stock Up 0.9 %
Shares of NYSE:JNJ opened at $149.91 on Tuesday. The stock has a market cap of $360.88 billion, a P/E ratio of 11.13, a P/E/G ratio of 3.00 and a beta of 0.58. The firm has a fifty day moving average price of $154.52 and a 200 day moving average price of $160.29. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.14. The firm had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. Sell-side analysts predict that Johnson & Johnson will post 10.1 EPS for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s dividend payout ratio is currently 35.34%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- What is the Australian Securities Exchange (ASX)
- Safeguard your portfolio with these three bargain stocks
- How to Invest and Trade Chinese Stocks
- Membership clubs gain leverage for the consumer rebound
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.